RNAi market not slowing down
The promise of RNA interference (RNAi) therapeutics has vastly increased scientific interest in the field. According to a report recently published by US company BioInformatics, 'The Market for RNA Interference Products: Challenges and Opportunities', increased activity by current practitioners as well as an influx of new users will fuel rapid growth in the market for RNAi research products over the next year.
The report details RNAi experimental design with a special focus on customers' experiences with pre-designed, validated or library siRNA duplexes, chemically synthesised custom siRNAs and transfection reagents.
According to the scientists surveyed, Ambion, Dharmacon, Invitrogen and Qiagen dominate the market for RNAi products.